Register Now | Learn how Optimer ligands can be developed in a biomarker-free way to open up new targets for challenging diseases
Register Now | Learn how Optimer ligands can be developed in a biomarker-free way to open up new targets for challenging diseases
28 October 2022 | Friday | News
Find out how Optimer binders cut 70% of the timelines compared to traditional antibody reagents
Image Source : Public Domain
Speakers
Dr David Bunka
Chief Technical Officer
Synopsis
Developing new assays, engaging new targets and accurately detecting specific biomarkers is difficult without fit-for-purpose ligands. While antibodies have long been the accepted gold standard, a number of drawbacks are inherent in their development and production that limit their use in some circumstances. Optimer ligands are aptamers optimized to overcome many of these issues for a wider target range, rapid development, improved manufacturability and batch consistency. Watch this webinar to understand how this technology is being applied to new assays and targets.
In this webinar, you will learn about
Learn how Optimer ligands can be customized specifically for the required target, assay and application through our flexible platform and toolkit for the best performance and integration
Find out how Optimer binders cut 70% of the timelines compared to traditional antibody reagents
Learn how Optimer ligands can be developed in a biomarker-free way to open up new targets for challenging diseases
Learn about Optimer applications for new diagnostics, affinity purification and targeted delivery of small molecule and gene therapy payloads